We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Follow-on Biologics Makers Lose on Senate Bill Exclusivity
Follow-on Biologics Makers Lose on Senate Bill Exclusivity
November 24, 2009
In a blow to generic-drug manufacturers, the Senate’s $849 billion healthcare overhaul
legislation, like the House version, gives biologics innovators 12 years of exclusivity.